Monogram Technologies Inc. Q3 2025 Earnings Call Transcript

Monogram Technologies Inc. (MGRM) held a shareholder/analyst call on September 30, 2025. Chairman of the Board, President & CEO Benjamin Sexson discussed the company's business and presented prepared remarks, including an introduction of the Board members and executive management team. Sexson also mentioned the format and rules of the meeting and reported on the formal steps taken in connection with the meeting.

Monogram Technologies Inc. (MGRM) held a shareholder/analyst call on September 30, 2025, with the Chairman of the Board, President & CEO Benjamin Sexson providing an overview of the company's business and strategic plans. The call was attended by various stakeholders to discuss the company's recent developments and future prospects.

Sexson began the call by welcoming attendees and introducing the Board members and executive management team. He also outlined the format and rules of the meeting, ensuring transparency and adherence to regulatory guidelines. The call focused on the company's recent acquisition of Monogram Technologies, which was finalized in July 2025 for approximately $177 million Zimmer Biomet, Medtech Mergers And Acquisitions Accelerate^[2].

The acquisition of Monogram Technologies, a developer of an FDA-cleared robotic system for total knee replacement, is expected to significantly enhance Monogram's product portfolio. Zimmer Biomet, the acquiring company, plans to commercialize the robotic system with its implants by 2027. This strategic move aligns with the broader trend of consolidation in the medical technology sector, driven by a desire to innovate and diversify portfolios Zimmer Biomet, Medtech Mergers And Acquisitions Accelerate^[2].

Sexson also touched upon the current state of the merger and acquisition market in the medical technology sector. According to industry experts, while early-stage acquisitions have slowed, large medtech deals remain strong, particularly where intellectual property can provide long-term value. The first quarter of 2025 saw 57 medtech transactions valued at more than $9.2 billion, the most active period since early 2022 Zimmer Biomet, Medtech Mergers And Acquisitions Accelerate^[2].

The call concluded with a Q&A session, where analysts and shareholders had the opportunity to ask questions and seek clarifications on various aspects of the company's operations and future plans. Sexson's presentation and the subsequent discussion provided a comprehensive update on Monogram Technologies' strategic direction and the broader market trends influencing the medical technology sector.